Literature DB >> 8119021

Hip arthroplasty for osteonecrosis after renal transplantation.

W J Murzic1, D E McCollum.   

Abstract

The treatment of osteonecrosis in renal-transplant patients with hip arthroplasty was reviewed. From 1972 to 1988, the surgical treatment evolved from the use of cemented total hip arthroplasty (THA) to uncemented bipolar hemiarthroplasty to, most recently, porous-ingrowth THA. During this period, 46 patients had 77 hip arthroplasties. Cemented replacement was used in 32 hips, uncemented bipolar replacement in 32, and porous-ingrowth arthroplasty in 13. At the two- to 18-year follow-up evaluations, the average Harris hip rating was 89 points. Ratings averaged 82 points at 8.7 years in cemented hips, 91 points at six years in bipolar hips, and 90 points at 3.1 years in uncemented hips. Loosening occurred in 46% of hips with cemented total hip prostheses, 9% of hips with bipolar prostheses, and in no hips with porous-ingrowth components. Aseptic revision rates were 31%, 12.5%, and 0% respectively. Infection rates were 0%, 9%, and 10% respectively. Although the follow-up period was shorter for bipolar and uncemented THAs, uncemented bipolar hemiarthroplasty and porous-ingrowth THA may be reasonable alternatives for the renal-transplant patient with osteonecrosis rather than cemented THA, which has a high long-term failure rate. The early results of porous-coated hip arthroplasty are satisfactory in patients with a functioning renal transplant.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8119021

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  12 in total

1.  Hip resurfacing in patients who have osteonecrosis and are 25 years or under.

Authors:  Siraj A Sayeed; Aaron J Johnson; D Alex Stroh; Thomas P Gross; Michael A Mont
Journal:  Clin Orthop Relat Res       Date:  2011-06       Impact factor: 4.176

2.  Uncemented porous-coated anatomic total hip replacement in Chinese patients.

Authors:  K H Chiu; W Y Shen; K M Chan
Journal:  Int Orthop       Date:  1995       Impact factor: 3.075

Review 3.  Osteonecrosis is not a predictor of poor outcomes in primary total hip arthroplasty: a systematic literature review.

Authors:  Henning R Johannson; Michael G Zywiel; David R Marker; Lynne C Jones; Mike S McGrath; Michael A Mont
Journal:  Int Orthop       Date:  2010-02-25       Impact factor: 3.075

4.  Total hip arthroplasty in steroid-induced osteonecrosis: early functional and radiological outcomes.

Authors:  Wael A Rahman; Donald S Garbuz; Bassam A Masri
Journal:  Can J Surg       Date:  2013-02       Impact factor: 2.089

5.  The Impact of Solid Organ Transplant History on Inpatient Complications, Mortality, Length of Stay, and Cost for Primary Total Hip Arthroplasty Admissions in the United States.

Authors:  Suparna M Navale; Caleb R Szubski; Alison K Klika; Nicholas K Schiltz; Pratik P Desai; Wael K Barsoum
Journal:  J Arthroplasty       Date:  2016-11-10       Impact factor: 4.757

6.  SAS weekly rounds: avascular necrosis.

Authors:  Thomas W Hamilton; Susan M Goodman; Mark Figgie
Journal:  HSS J       Date:  2009-03-18

Review 7.  Identification and preoperative optimization of risk factors to prevent periprosthetic joint infection.

Authors:  Seung-Hoon Baek
Journal:  World J Orthop       Date:  2014-07-18

8.  Minimum ten-year follow-up of cemented total hip replacement in patients with osteonecrosis of the femoral head.

Authors:  Thomas M Fyda; John J Callaghan; Jason Olejniczak; Richard C Johnston
Journal:  Iowa Orthop J       Date:  2002

9.  Joint replacement in X-linked hypophosphatemia.

Authors:  Emily S Mills; Louis Iorio; Richard S Feinn; Kevin M Duignan; Carolyn M Macica
Journal:  J Orthop       Date:  2018-12-21

10.  Treatment of femoral head osteonecrosis in the United States: 16-year analysis of the Nationwide Inpatient Sample.

Authors:  Aaron J Johnson; Michael A Mont; Audrey K Tsao; Lynne C Jones
Journal:  Clin Orthop Relat Res       Date:  2014-02       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.